BRIEF-First Venture Sweden Private Says Sprint Bioscience Sells Cancer Program TREX1 To Gilead Sciences

Reuters
Nov 24
BRIEF-First Venture Sweden Private Says Sprint Bioscience Sells Cancer Program TREX1 To <a href="https://laohu8.com/S/GILD">Gilead</a> Sciences

Nov 24 (Reuters) - First Venture Sweden Private AB FIRSTb.ST:

  • SPRINT BIOSCIENCE SELLS CANCER PROGRAM TREX1 TO GILEAD SCIENCES

  • DEAL INCLUDES $14 MILLION UPFRONT AND UP TO $400 MILLION MILESTONES

Source text: ID:nMFN7fkTZ7

Further company coverage: [FIRSTb.ST]

(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10